REJECTION OF ALLOGENEIC-TUMOR IS NOT DETERMINED BY HOST RESPONSES TO MHC CLASS-I MOLECULES AND IS MEDIATED BY CD4-CD8+ LYMPHOCYTES-T THAT ARE NOT LYTIC FOR THE TUMOR

被引:8
作者
COLE, GA [1 ]
OSTRANDROSENBERG, S [1 ]
机构
[1] UNIV MARYLAND, DEPT BIOL SCI, CATONSVILLE, MD 21228 USA
关键词
D O I
10.1016/0008-8749(91)90319-7
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
In previous studies, the murine SaI (A/J derived, KkDd sarcoma was transfected with the allogeneic MHC class I H-2Kb gene, and expressed high levels of H-2Kb antigen. Contrary to expectations, the tumor cells expressing the alloantigen (SKB3.1M tumor cells) were not rejected by autologous A/J mice. Because these results contradict the laws of transplantation immunology, the present studies were undertaken to examine the immunogenicity of SKB3.1M and SaI cells in allogeneic hosts. Similar to SKB3.1M. SaI cells are lethal in some allogeneic strains, despite tumor-host MHC class I incompatibilities. Tumor challenges of SKB3.1M and SaI cells, however induce MHC class I-specific antibodies and CTL in both tumor-resistant and -susceptible hosts. Although the tumors induce specific CTL, tumor cells are not lysed in vitro by these CTL, suggesting that the tumor cells are resistant to CTL-mediated lysis. Since growth of these tumors does not follow the classical rules of allograft transplantation, and because the tumor is not susceptible to CTL-mediated lysis, we have used Winn assays to identify the effector lymphocyte(s) responsible for SaI rejection. Depletion studies demonstrate that the effector cell is a CD4-CD8+ T lymphocyte. Collectively these studies suggest that the host's response to MHC class I alloantigens of SK-B3.1M and SaI cells does not determine tumor rejection, and that effector cells other than classically defined CTL, but with the CD4-CD8+ phenotype, can mediate tumor-specific immunity. © 1991.
引用
收藏
页码:480 / 490
页数:11
相关论文
共 22 条
[1]   SPECIFIC CYTOSTATIC EFFECT OF LYMPH-NODE CELLS FROM NORMAL AND T-CELL-DEFICIENT MICE ON SYNGENEIC TUMOR TARGET CELLS IN-VITRO AND ITS SPECIFIC ABROGATION BY BODY-FLUIDS FROM SYNGENEIC TUMOR-BEARING MICE [J].
CHIA, E ;
FESTENSTEIN, H .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1973, 3 (08) :483-487
[2]   ALLOGENEIC H-2-ANTIGEN EXPRESSION IS INSUFFICIENT FOR TUMOR REJECTION [J].
COLE, GA ;
COLE, GA ;
CLEMENTS, VK ;
GARCIA, EP ;
OSTRANDROSENBERG, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (23) :8613-8617
[3]  
DEBAETSELIER P, 1980, NATURE, V288, P179
[4]  
DIALYNAS DP, 1983, J IMMUNOL, V131, P2445
[5]  
DUNHAM LJ, 1953, JNCI-J NATL CANCER I, V13, P1299
[6]  
ELLIOTT BE, 1989, ADV CANCER RES, V53, P181
[7]   VARIATION IN MHC ANTIGENIC PROFILES OF TUMOR-CELLS AND ITS BIOLOGICAL EFFECTS [J].
FESTENSTEIN, H ;
SCHMIDT, W .
IMMUNOLOGICAL REVIEWS, 1981, 60 :85-127
[8]   QAT-4 AND QAT-5, NEW MURINE T-CELL ANTIGENS GOVERNED BY THE TLA REGION AND IDENTIFIED BY MONOCLONAL ANTIBODIES [J].
HAMMERLING, GJ ;
HAMMERLING, U ;
FLAHERTY, L .
JOURNAL OF EXPERIMENTAL MEDICINE, 1979, 150 (01) :108-116
[9]   REJECTION OF TRANSPLANTABLE AKR LEUKEMIA-CELLS FOLLOWING MHC DNA-MEDIATED CELL-TRANSFORMATION [J].
HUI, K ;
GROSVELD, F ;
FESTENSTEIN, H .
NATURE, 1984, 311 (5988) :750-752
[10]  
HUI KM, 1989, J IMMUNOL, V143, P3835